Keyword: Johnson & Johnson
When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.
Gilead has reaped billions of dollars in sales from "unlawfully monopolized" HIV drugs, patients and activists say in a new class action lawsuit.
Patients with treatment-resistant depression have a new option in J&J's Spravato, but the cost watchdogs at ICER say it's not cost-effective.
Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
As drugmakers count on their growing SGLT2 diabetes drugs, researchers are tracking cases of a flesh-eating genital infection in patients using them.
With an Ebola outbreak in Congo outrunning vaccination efforts, the WHO wants to use an experimental drug from Johnson & Johnson.
Novartis hopes the deal, potentially worth $5.3 billion, could better position itself in front-of-the-eye therapies.
It’s official. HHS will require pharma companies to include list prices in TV ads—and the industry will have just over two months to do it.
J&J’s commissioned film about the early days of the AIDS epidemic is set to attract a wider audience, thanks to a Verizon Media distribution deal.
Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a leg up. New clinical data show promise in leukemia.